Reckitt (LSE:RKT) Benckiser has spent the past two years trying to convince investors that a leaner, more focused consumer-health Business lies beneath years of underperformance, and its half-year results in late July 2026 offered the clearest evidence yet that the recovery trade may have legs. The shares rose around 4.6% on the day the numbers were presented, as the market welcomed a Q2 sales acceleration and confirmation that the group's long-promised reshaping is finally being delivered.
The headline growth figures were modest but improving. Like-for-like net Revenue rose 2.6% in the first half, with the core Reckitt (LSE:RKT) portfolio up 2.7%, but the more important detail was the trajectory: core like-for-like growth accelerated to 4.2% in the second quarter from just 1.3% in the first, suggesting momentum is building as weaker comparatives and a soft cold-and-flu season wash through. Group net revenue for the half was around £6.4 billion. Management reiterated full-year guidance of 4-5% like-for-like growth for core Reckitt and an adjusted Operating Margin between roughly 24.9% and 25.6%.
Reshaping the portfolio
The strategic story is arguably more important than any single quarter. Reckitt has been executing a plan to concentrate on its higher-margin, faster-growing health and hygiene brands — names such as Nurofen, Strepsils, Gaviscon, Durex, Dettol and Finish — while stepping away from lower-growth categories. During the first half it completed the separation of its Essential Home business (the portfolio of cleaning brands including Air Wick and Cillit Bang), a milestone that funded a £1.6 billion Special Dividend to shareholders and simplified the group, albeit leaving some stranded costs that management expects to resolve by 2027. The infant-nutrition arm, Mead Johnson, remains under review as the company weighs its long-term fit.
Capital returns have been generous. Including the special dividend, Ordinary Dividends and buybacks, Reckitt returned around £3 billion to shareholders in the first half, and it launched a fresh £500 million buyback programme covering the next twelve months. For a stock that has frustrated holders, this steady stream of cash returns has helped underpin sentiment while the operational turnaround plays out.
The recovery-trade question
The bull case is that Reckitt owns a stable of trusted, everyday brands with pricing power, that portfolio simplification will lift margins and growth, and that the shares have been unloved enough to offer recovery potential if execution improves. The Q2 acceleration and completed disposals lend that argument support. The margin picture, however, is a reminder that this is not a straight line: the core adjusted operating margin slipped around 100 basis points year on year in the first half, and gross margin was down about 110 basis points, reflecting input-cost and mix pressures that the company must offset through efficiency and pricing.
The risks are real. Consumer-health Demand can be volatile — a mild cold-and-flu season alone can knock a percentage point off growth — and Reckitt competes against formidable rivals in every category. The unresolved question over Mead Johnson, which has been a source of litigation and Volatility in the United States, still hangs over the shares. Emerging-market currencies, private-label competition and input-cost Inflation all add uncertainty, and the group's credibility with investors was dented by past guidance disappointments, leaving little tolerance for further stumbles.
For now, the direction of travel is encouraging: growth is accelerating, the portfolio is simpler, margins are being defended and cash is flowing back to shareholders. Whether this amounts to a durable recovery or merely a better quarter will depend on the second half — specifically whether core growth holds near the top of the guided range, whether margins stabilise, and what management decides to do with Mead Johnson. After years of false dawns, Reckitt is at least giving the recovery thesis something to work with.






Please wait processing your request...